FREE SHIPPING over $40
OVER 10000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Drug testing and analysis2025; doi: 10.1002/dta.3899

Transcriptomic Biomarkers in Blood Indicative of the Administration of Recombinant Human Erythropoietin to Thoroughbred Horses.

Abstract: Erythropoiesis-stimulating agents (ESAs) continue to be a significant threat to the integrity of human and equine sports. Besides conventional direct testing, monitoring the biomarkers associated with the effects of ESAs may provide a complementary approach via indirect detection to enhance doping control. In this study, we applied RNA-sequencing (RNA-seq) to discover blood RNA biomarkers in Thoroughbred horses after administration with a long-acting form of recombinant human erythropoietin (rhEPO), methoxy polyethylene glycol epoetin beta, Mircera®. A single subcutaneous administration of Mircera® at ~ 4.2 μg/kg was effective in elevating haematocrit, haemoglobin and erythrocyte levels to varying extents in as early as 4 days post-administration in all three horses, which persisted for 40 days post-administration (the last sample collected). RNA-seq was applied to analyse blood transcriptomic changes. Differential gene expression analysis has allowed the identification of 46 genes that showed dramatic and temporary upregulation at 4-11 days after Mircera® administration. STRING analysis has identified the functional enrichment of 15 genes important for erythropoiesis and erythrocyte function, supporting the idea of an increased release into the peripheral circulation of residual RNA-containing reticulocytes after rhEPO exposure, which would otherwise mature normally inside the bone marrow in horses. Machine learning of blood transcriptomes has enabled the discrimination of samples with or without Mircera administration. Therefore, our study has provided new insights into the biological mechanism of erythropoiesis caused by rhEPO administration in horses and has provided evidence supporting the control of misuse of ESAs by monitoring the equine blood transcriptome.
© 2025 John Wiley & Sons Ltd.
Get Full Text
Publication Date: 2025-04-21 PubMed ID: 40256823DOI: 10.1002/dta.3899Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research investigates how to detect erythropoiesis-stimulating agent (ESA) use in racehorses by studying transcriptomic biomarkers. The study discovered that residual RNA-containing reticulocytes entered the bloodstream after the administration of an ESA, leading to potentially detectable markers of ESA misuse.

Introduction to the Problem

  • ESAs, which artificially improve athletic performance, are a significant concern in both human and equine sports. Direct testing may sometimes fail to detect ESA use due to the small window of detection, hence necessitating complementary indirect detection methods.
  • The study focused on identifying blood RNA biomarkers in thoroughbred horses after administering recombinant human erythropoietin (rhEPO), a long-acting form of ESA. This was done to gain insight into the biological processes induced by rhEPO and establish an indirect method for detecting its use.

Methodology

  • The researchers applied RNA-Sequencing (RNA-seq) to analyze the changes in the blood transcriptome (the full set of RNA sequences) of thoroughbred horses upon injection of methoxy polyethylene glycol epoetin beta, also known as Mircera®, a type of rhEPO.
  • A single administration of Mircera® at about 4.2 µg/kg significantly increased the hematocrit, hemoglobin, and erythrocyte levels in all three horses as early as 4 days post injection till 40 days after (the duration of sample collection).

Findings

  • Differential gene expression analysis identified 46 genes that showed sudden and temporary upregulation 4-11 days after Mircera® administration.
  • By using the STRING analysis, the study found a functional enrichment of 15 genes crucial for erythropoiesis and erythrocyte function, supporting the hypothesis that the rhEPO administration induced residuals of RNA-containing reticulocytes to be released into the peripheral blood circulation – these cells would otherwise mature normally inside bone marrow in horses.
  • Machine learning techniques allowed researchers to distinguish between blood sample with and without Mircera administration based on the observed transcriptomic changes.

Conclusion

  • The study provides new insights into the biological mechanism of erythropoiesis due to rhEPO administration in horses and presents preliminary evidence for controlling the misuse of ESAs by monitoring the equine blood transcriptome.
  • This transcriptomic monitoring potentially allows detection of Mircera use beyond the typically available window for direct testing and could help ensure the integrity of equine sports.

Cite This Article

APA
Cheung HW, Wong KS, Cheng PCF, Tsang CYN, Farrington AF, Wan TSM, Ho ENM. (2025). Transcriptomic Biomarkers in Blood Indicative of the Administration of Recombinant Human Erythropoietin to Thoroughbred Horses. Drug Test Anal. https://doi.org/10.1002/dta.3899

Publication

Drug testing and analysis
ISSN: 1942-7611
NlmUniqueID: 101483449
Country: England
Language: English

Researcher Affiliations

Cheung, Hiu Wing
  • Racing Laboratory, the Hong Kong Jockey Club, Sha Tin Racecourse, Sha Tin, N. T., Hong Kong, China.
Wong, Kin-Sing
  • Racing Laboratory, the Hong Kong Jockey Club, Sha Tin Racecourse, Sha Tin, N. T., Hong Kong, China.
Cheng, Paul C F
  • Racing Laboratory, the Hong Kong Jockey Club, Sha Tin Racecourse, Sha Tin, N. T., Hong Kong, China.
Tsang, Candice Y N
  • Racing Laboratory, the Hong Kong Jockey Club, Sha Tin Racecourse, Sha Tin, N. T., Hong Kong, China.
Farrington, Adrian F
  • Veterinary Clinical Services, the Hong Kong Jockey Club, Sha Tin Racecourse, Sha Tin, N. T., Hong Kong, China.
Wan, Terence S M
  • Racing Laboratory, the Hong Kong Jockey Club, Sha Tin Racecourse, Sha Tin, N. T., Hong Kong, China.
Ho, Emmie N M
  • Racing Laboratory, the Hong Kong Jockey Club, Sha Tin Racecourse, Sha Tin, N. T., Hong Kong, China.

References

This article includes 41 references
  1. International Federation of Horseracing Authorities (IFHA), Article 6 of International Agreement on Breeding, Racing and Wagering (IABRW) (IFHA, 2024). Accessed March 30, 2025, https://ifhaonline.org/Default.asp?section=IABRW&area=2#article6.
  2. Wong JK, Wan TS. Doping Control Analyses in Horseracing: A Clinician's Guide. Veterinary Journal 200, no. 1 (2014): 8–16.
  3. Cawley AT, Keledjian J. Intelligence‐Based Anti‐Doping From an Equine Biological Passport. Drug Testing and Analysis 9, no. 9 (2017): 1441–1447.
  4. Reichel C. OMICS‐Strategies and Methods in the Fight Against Doping. Forensic Science International 213, no. 1–3 (2011): 20–34.
  5. International Federation of Horseracing Authorities (IFHA), Article 6A of International Agreement on Breeding, Racing and Wagering (IABRW) (IFHA, 2024). Accessed March 30, 2025, https://ifhaonline.org/Default.asp?section=IABRW&area=2#article6a.
  6. Elliott S. Erythropoiesis‐Stimulating Agents and Other Methods to Enhance Oxygen Transport. British Journal of Pharmacology 154, no. 3 (2008): 529–541.
  7. Beuck S, Schänzer W, Thevis M. Hypoxia‐Inducible Factor Stabilizers and Other Small‐Molecule Erythropoiesis‐Stimulating Agents in Current and Preventive Doping Analysis. Drug Testing and Analysis 4, no. 11 (2012): 830–845.
  8. Wilkin T, Baoutina A, Hamilton N. Equine Performance Genes and the Future of Doping in Horseracing. Drug Testing and Analysis 9, no. 9 (2017): 1456–1471.
  9. Durussel J, Haile DW, Mooses K. Blood Transcriptional Signature of Recombinant Human Erythropoietin Administration and Implications for Antidoping Strategies. Physiological Genomics 48, no. 3 (2016): 202–209.
  10. Salamin O, Gottardo E, Schobinger C. Detection of Stimulated Erythropoiesis by the RNA‐Based 5′‐Aminolevulinate Synthase 2 Biomarker in Dried Blood Spot Samples. Clinical Chemistry 65, no. 12 (2019): 1563–1571.
  11. Wang G, Durussel J, Shurlock J. Validation of Whole‐Blood Transcriptome Signature During Microdose Recombinant Human Erythropoietin (rHuEpo) Administration. BMC Genomics 18, no. 8 (2017): 817.
  12. Loria F, Manfredi M, Reverter‐Branchat G, Segura J, Kuuranne T, Leuenberger N. Automation of RNA‐Based Biomarker Extraction From Dried Blood Spots for the Detection of Blood Doping. Bioanalysis 12, no. 11 (2020): 729–736.
  13. Loria F, Stutz AP, Rocca A. Monitoring of Hemoglobin and Erythropoiesis‐Related mRNA With Dried Blood Spots in Athletes and Patients. Bioanalysis 14, no. 5 (2022): 241–251.
  14. Loup B, André F, Leuenberger N. New Transcriptomic Biomarkers for Detection of the Recombinant Human Erythropoietin (rHuEPO) MirCERA in Horses. Drug Testing and Analysis (2024).
    doi: 10.1002/dta.3812google scholar: lookup
  15. Bailly‐Chouriberry L, Noguier F, Manchon L. Blood Cells RNA Biomarkers as a First Long‐Term Detection Strategy for EPO Abuse in Horseracing. Drug Testing and Analysis 2, no. 7 (2010): 339–345.
  16. Dahlgren AR, Knych HK, Arthur RM, Durbin‐Johnson BP, Finno CJ. Transcriptomic Markers of Recombinant Human Erythropoietin micro‐Dosing in Thoroughbred Horses. Genes (Basel) 12, no. 12 (2021): 1874.
  17. Evans C, Hardin J, Stoebel DM. Selecting Between‐Sample RNA‐Seq Normalization Methods From the Perspective of Their Assumptions. Brief Bioinformatics 19, no. 5 (2018): 776–792.
  18. Cheung HW, Wong KS, Cheng PCF, Wan TSM, Ho ENM. Equine Blood Transcriptomic Profiling to Discover Biomarkers for Equine Doping Control: Evaluation of RNA‐Sequencing Data Normalization Strategy. Proceedings of 23rd International Conference of Racing Analysts and Veterinarians Hong Kong, 2023.
  19. Joré C, Loup B, Garcia P. Liquid Chromatography ‐ High Resolution Mass Spectrometry‐Based Metabolomic Approach for the Detection of Continuous Erythropoiesis Receptor Activator Effects in Horse Doping Control. Journal of Chromatography a 1521 (2017): 90–99.
  20. Cheung HW, Wong KS, Tam JCL. Discovery of Biomarkers of a Recombinant Human Erythropoietin Administration to Thoroughbred Geldings by Label‐Free Proteomics. Drug Testing and Analysis (2024).
    doi: 10.1002/dta.3810google scholar: lookup
  21. Liu Y, Zhou J, White KP. RNA‐Seq Differential Expression Studies: More Sequence or More Replication?. Bioinformatics 30, no. 3 (2014): 301–304.
  22. Zhang Y, Parmigiani G, Johnson WE. ComBat‐Seq: Batch Effect Adjustment for RNA‐Seq Count Data. NAR Genomics & Bioinformatics 2, no. 3 (2020): lqaa078.
  23. Love MI, Huber W, Anders S. Moderated Estimation of Fold Change and Dispersion for RNA‐Seq Data With DESeq2. Genome Biology 15, no. 12 (2014): 550.
  24. Conesa A, Madrigal P, Tarazona S. A Survey of Best Practices for RNA‐Seq Data Analysis. Genome Biology 17 (2016): 13.
  25. Szklarczyk D, Kirsch R, Koutrouli M. The STRING database in 2023: Protein‐Protein Association Networks and Functional Enrichment Analyses for any Sequenced Genome of Interest. Nucleic Acids Research 51, no. D1 (2023): D638–d646.
  26. Kuhn M. Building Predictive Models in R Using the Caret Package. Journal of Statistical Software 28, no. 5 (2008): 26.
  27. Kukurba KR, Montgomery SB. RNA Sequencing and Analysis. Cold Spring Harbor Protocols 2015, no. 11 (2015): 951–969.
  28. Bunn HF. Subunit Assembly of Hemoglobin: An Important Determinant of Hematologic Phenotype. Blood 69, no. 1 (1987): 1–6.
  29. Sadlon TJ, Dell'Oso T, Surinya KH, May BK. Regulation of Erythroid 5‐Aminolevulinate Synthase Expression During Erythropoiesis. International Journal of Biochemistry & Cell Biology 31, no. 10 (1999): 1153–1167.
  30. Yien YY, Perfetto M. Regulation of Heme Synthesis by Mitochondrial Homeostasis Proteins. Frontiers in Cell and Developmental Biology 10, no (2022): 895521.
  31. Lindskog S. Structure and Mechanism of Carbonic Anhydrase. Pharmacology & Therapeutics 74, no. 1 (1997): 1–20.
  32. Iolascon A, Andolfo I, Russo R. Advances in Understanding the Pathogenesis of red Cell Membrane Disorders. British Journal of Haematology 187, no. 1 (2019): 13–24.
  33. Weiss MJ, dos Santos CO. Chaperoning Erythropoiesis. Blood 113, no. 10 (2009): 2136–2144.
  34. Andolfo I, Russo R, Gambale A, Iolascon A. New Insights on Hereditary Erythrocyte Membrane Defects. Haematologica 101, no. 11 (2016): 1284–1294.
  35. Mei Y, Liu Y, Ji P. Understanding Terminal Erythropoiesis: An Update on Chromatin Condensation, Enucleation, and Reticulocyte Maturation. Blood Reviews 46 (2021): 100740.
  36. Stevens‐Hernandez CJ, Bruce LJ. Reticulocyte Maturation. Membranes (Basel) 12, no. 3 (2022): 311.
  37. Correia CN, McLoughlin KE, Nalpas NC. RNA Sequencing (RNA‐Seq) Reveals Extremely low Levels of Reticulocyte‐Derived Globin Gene Transcripts in Peripheral Blood From Horses (Equus Caballus) and Cattle (Bos Taurus). Frontier Genetics 9 (2018): 278.
  38. Cooper C, Sears W, Bienzle D. Reticulocyte Changes After Experimental Anemia and Erythropoietin Treatment of Horses. Journal of Applied Physiology 99, no. 3 (2005): 915–921.
  39. Tablin F, Weiss L. Equine Bone Marrow: A Quantitative Analysis of Erythroid Maturation. Anatomical Record 213, no. 2 (1985): 202–206.
  40. Huang S, Cai N, Pacheco PP, Narrandes S, Wang Y, Xu W. Applications of Support Vector Machine (SVM) Learning in Cancer Genomics. Cancer Genomics Proteomics 15, no. 1 (2018): 41–51.
  41. Salah HT, Muhsen IN, Salama ME, Owaidah T, Hashmi SK. Machine Learning Applications in the Diagnosis of Leukemia: Current Trends and Future Directions. International Journal of Laboratory Hematology 41, no. 6 (2019): 717–725.

Citations

This article has been cited 1 times.
  1. Sakellariou P, Walpurgis K, Thomas A, Marchand A, Miller G, Dellanna F, Thevis M. Combined detection of inhibitors of the activin receptor signaling pathways (IASPs) by means of LC-HRMS/MS for human doping control. Sci Rep 2025 Jun 6;15(1):19887.
    doi: 10.1038/s41598-025-03562-ypubmed: 40481031google scholar: lookup
Subscribe to our newsletter
Join 99,727 horse owners like you who receive our email updates on horse health and nutrition.